[Progress in therapy for and diagnosis of diabetic complications--diabetic retinopathies].
Funatsu
Hideharu
H
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D015195:Drug Design; D006801:Humans; D009389:Neovascularization, Pathologic; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology / Q000502:physiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; C495058:pegaptanib; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab